Cova I, Di Battista M E, Vanacore N, Papi C P, Alampi G, Rubino A, Valente M, Meco G, Contri P, Di Pucchio A, Lacorte E, Priori A, Mariani C, Pomati S
Institute of Clinical Neurology, Department of Clinical Sciences, ASST Fatebenefratelli-Sacco, "Luigi Sacco" University Hospital, Milan, Italy; Neurology Unit, Department of Health Sciences, ASST Santi Paolo e Carlo, "San Paolo" University Hospital, Milan, Italy.
Department of Neurology and Psychiatry (Parkinson's Centre) and Research Centre of Social Diseases (CIMS), "Sapienza" University, Rome, Italy; Cognitive Impairment Center, Local Health Authority 9 of Treviso, Treviso, Italy.
Parkinsonism Relat Disord. 2017 Jan;34:38-42. doi: 10.1016/j.parkreldis.2016.10.020. Epub 2016 Oct 24.
To validate the adapted Italian version of the Non-Motor Symptoms Scale (NMSS), a tool to assess non-motor symptoms (NMS) in Parkinson's disease (PD).
A cross cultural adaptation of the NMSS into Italian and a psychometric analysis of the translated version of the NMSS was carried out in patients with PD from two university centres-affiliated hospitals. The quality of data and the acceptability, reliability and construct validity of NMSS were analyzed. The following standard scales were also applied: Hoehn and Yahr staging, Unified Parkinson's Disease Rating Scale (UPDRS) part III, Montreal Cognitive Assessment, Beck Depression Inventory, Neuropsychiatric Inventory, Epworth Sleepiness Scale, Autonomic Scale for Outcomes in Parkinson's disease-Motor, Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale part I and Modified Cumulative Illness Rating Scale (CIRS). Levodopa equivalent daily dose (LEDD) was calculated.
Seventy-one patients with PD were assessed (mean age years 69.8 ± 9.6 SD; 31% women; mean length of disease 6.3 ± 4.6 years; H&Y median: 2). Mean NMSS was 39.76 (SD 31.9; skewness 0.95). The total score of NMSS was free of floor or ceiling effects and showed a satisfactory reliability (Cronbach's alpha coefficient on total score was 0.72 [range for domains: 0.64-0.73], SEM value was 3.88 [½ SD = 31.90]). Significant positive correlations were found among total NMSS and other NMS standard tests, but no significant correlation appeared with UPDRS part III, CIRS and LEDD.
The Italian NMSS is a comprehensive and helpful measure for NMS in native Italian patients with PD.
验证帕金森病非运动症状量表(NMSS)的意大利语改编版,该量表用于评估帕金森病(PD)的非运动症状(NMS)。
对NMSS进行跨文化改编,使其适用于意大利语,并在两所大学附属医院的帕金森病患者中对NMSS的翻译版本进行心理测量分析。分析了数据质量以及NMSS的可接受性、信度和结构效度。还应用了以下标准量表:Hoehn和Yahr分期、统一帕金森病评定量表(UPDRS)第三部分、蒙特利尔认知评估量表、贝克抑郁量表、神经精神科问卷、爱泼沃斯思睡量表、帕金森病运动自主量表、运动障碍协会赞助修订的统一帕金森病评定量表第一部分以及改良累积疾病评定量表(CIRS)。计算左旋多巴等效日剂量(LEDD)。
共评估了71例帕金森病患者(平均年龄69.8±9.6岁;女性占31%;平均病程6.3±4.6年;H&Y中位数:2)。NMSS平均分为39.76(标准差31.9;偏度0.95)。NMSS总分无地板效应或天花板效应,信度良好(总分的Cronbach's α系数为0.72[各领域范围:0.64 - 0.73],标准误值为3.88[½标准差 = 31.90])。NMSS总分与其他非运动症状标准测试之间存在显著正相关,但与UPDRS第三部分、CIRS和LEDD无显著相关性。
意大利语版NMSS是评估意大利本土帕金森病患者非运动症状的一种全面且有用的测量工具。